within Pharmacolibrary.Drugs.ATC.H;

model H01CB03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003916666666666667,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01CB03</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lanreotide is a long-acting somatostatin analog used in the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and symptoms associated with carcinoid syndrome. It is typically administered as a deep subcutaneous or intramuscular injection. Lanreotide is approved for use in many countries and is a clinically used drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects and patients with acromegaly after single deep subcutaneous injection.</p><h4>References</h4><ol><li><p>Antonijoan, RM, et al., &amp; Montes, M (2004). Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. <i>The Journal of pharmacy and pharmacology</i> 56(4) 471–476. DOI:<a href=\"https://doi.org/10.1211/0022357023123\">10.1211/0022357023123</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15099442/\">https://pubmed.ncbi.nlm.nih.gov/15099442</a></p></li><li><p>Hu, M, &amp; Tomlinson, B (2010). Pharmacokinetic evaluation of lanreotide. <i>Expert opinion on drug metabolism &amp; toxicology</i> 6(10) 1301–1312. DOI:<a href=\"https://doi.org/10.1517/17425255.2010.513700\">10.1517/17425255.2010.513700</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20716034/\">https://pubmed.ncbi.nlm.nih.gov/20716034</a></p></li><li><p>Kyriakakis, N, et al., &amp; Murray, RD (2014). Lanreotide autogel in acromegaly - a decade on. <i>Expert opinion on pharmacotherapy</i> 15(18) 2681–2692. DOI:<a href=\"https://doi.org/10.1517/14656566.2014.970173\">10.1517/14656566.2014.970173</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25307803/\">https://pubmed.ncbi.nlm.nih.gov/25307803</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01CB03;
